Bibliographic Details
| Title: |
Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC |
| Authors: |
Anne Mc Leer, PhD, Julie Mondet, PharmD, PhD, Nelly Magnat, MSc, Mailys Mersch, MSc, Diane Giovannini, MD, Camille Emprou, MD, Anne-Claire Toffart, MD, PhD, Nathalie Sturm, MD, PhD, Sylvie Lantuéjoul, MD, PhD, David Benito, PhD |
| Source: |
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100714- (2024) |
| Publisher Information: |
Elsevier, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
RET, Fusion gene, Lung cancer, FISH, RNA-sequencing, Targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Introduction: RET rearrangements occur in 1% to 2% NSCLCs. Since no clinically validated RET antibody is currently available, fluorescence in situ hybridization (FISH) is often used as a screening tool to identify patients likely to benefit from RET-targeted therapy. In this study, we performed a comprehensive review of publications in which RET-rearrangement testing was performed by FISH and compared the methods and results with our data. Methods: The findings of an electronic search for publications using RET-FISH in lung cancer were compared with the results obtained at the Grenoble University Hospital where 784 EGFR-, KRAS-, ALK-, and ROS1-negative NSCLCs were tested by RET break-apart FISH and confirmed by RNA-sequencing (RNA-seq). Results: Out of the 85 publications using RET-FISH analysis, 52 pertained to patients with lung cancer. The most often used positivity threshold was 15%. Six publications compared RET-FISH with at least one other molecular technique on at least eight samples, and the concordance was variable, from 5.9% to 66.7% for FISH-positive cases. Regarding our data, out of the 784 analyzed samples, 32 (4%) were positive by RET-FISH. The concordance between RET-FISH and RNA-seq in RET-FISH positive samples was 69%. Conclusions: Overall, both existing literature and our data suggest that RET-FISH testing can be used for rapid screening of RET rearrangements in NSCLC. Nevertheless, using an orthogonal technique such as RNA-seq to confirm RET-FISH-positive cases is essential for ensuring that only patients likely to benefit from RET-target therapy receive the treatment. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2666-3643 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2666364324000845; https://doaj.org/toc/2666-3643 |
| DOI: |
10.1016/j.jtocrr.2024.100714 |
| Access URL: |
https://doaj.org/article/4980913fe42d45de90e92091df11b88f |
| Accession Number: |
edsdoj.4980913fe42d45de90e92091df11b88f |
| Database: |
Directory of Open Access Journals |
